Verona Pharma (NASDAQ:VRNA - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, April 29th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $41.47 million for the quarter.
Verona Pharma Trading Up 1.0 %
Shares of Verona Pharma stock traded up $0.68 during trading hours on Friday, reaching $65.46. The stock had a trading volume of 766,895 shares, compared to its average volume of 1,226,537. The firm has a market capitalization of $5.29 billion, a price-to-earnings ratio of -34.09 and a beta of 0.16. Verona Pharma has a 1 year low of $11.39 and a 1 year high of $70.40. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. The firm has a 50 day simple moving average of $62.40 and a two-hundred day simple moving average of $50.55.
Analyst Ratings Changes
Several equities research analysts have issued reports on the stock. Truist Financial reiterated a "buy" rating and set a $57.00 price objective (up from $44.00) on shares of Verona Pharma in a research note on Wednesday, January 8th. Cantor Fitzgerald assumed coverage on Verona Pharma in a report on Monday. They issued an "overweight" rating and a $80.00 price target for the company. Roth Capital set a $83.00 price objective on Verona Pharma in a research report on Friday, February 28th. Roth Mkm started coverage on Verona Pharma in a research report on Friday, January 10th. They issued a "buy" rating and a $68.00 target price for the company. Finally, Canaccord Genuity Group raised their target price on Verona Pharma from $44.00 to $72.00 and gave the company a "buy" rating in a report on Wednesday, February 12th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $75.43.
View Our Latest Research Report on Verona Pharma
Insiders Place Their Bets
In other Verona Pharma news, insider Kathleen A. Rickard sold 79,264 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $8.35, for a total transaction of $661,854.40. Following the completion of the transaction, the insider now directly owns 2,608,976 shares of the company's stock, valued at $21,784,949.60. This trade represents a 2.95 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.80% of the stock is owned by company insiders.
About Verona Pharma
(
Get Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Further Reading
Before you consider Verona Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma wasn't on the list.
While Verona Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
